Navigating MPN Together: A Live Conversation with Dr. Aaron Gerds
Join us live for an interactive discussion with MPN expert Dr. Aaron Gerds. This open forum is your chance to ask questions and gain valuable insights about myeloproliferative neoplasms (MPNs), including diagnosis, symptoms, treatment options, and daily living. Patients and caregivers are encouraged to submit questions in advance and take part in this engaging Q&A session.
Dalton introduces the agenda of the event and our featured speaker Aaron Gerds, MD
Interactive discussion with Dr. Gerds to talk about MPN.
Type your questions in the chat and we will answer them!
Dalton Bean
Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Aaron Gerds, MD
Dr. Aarong Gerds is a hemotologist oncologist at the Cleveland Clinic Taussig Cancer Institute where they subspecialize in treating patients with myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), as well as myelodsyplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), with a special emphasis on allogeneic hematopoietic cell transplantation. Dr. Gerds is also an active member of the American Society of Hematology, participating in both the Advocacy Leadership Institute and Clinical Research Training Institute, as well as serving on the Test Materials Development Committee. As Assistant Professor in Medicine (Hematology and Medical Oncology) at the Cleveland Clinic Taussig Cancer Institute, Dr. Gerds serves as the principal investigator for a number of clinical trials for the treatment of MPNs, and is focused on developing novel therapies for these patients